Regenxbio (RGNX) Current Leases (2019 - 2025)

Regenxbio's Current Leases history runs 7 years deep, the most recent figure standing at $8.3 million for Q4 2025.

• On a quarterly basis, Current Leases rose 4.86% year-over-year to $8.3 million in Q4 2025; TTM through Dec 2025 was $8.3 million, a 4.86% increase from a year earlier, with the FY2025 full-year figure at $8.3 million, up 4.86% from the prior year.
• Current Leases fell to $8.3 million in Q4 2025 per RGNX's latest filing, from $9.1 million in the prior quarter.
• Across five years, Current Leases topped out at $9.1 million in Q3 2025 and bottomed at $1.3 million in Q3 2021.
• The 5-year median for Current Leases is $6.5 million (2023), against an average of $5.5 million.
• Across the five-year window, Current Leases plunged 62.71% in 2021 and jumped 242.29% in 2022, its largest moves.
• Year by year, Current Leases stood at $1.8 million in 2021, then soared by 242.29% to $6.0 million in 2022, then climbed by 17.86% to $7.1 million in 2023, then increased by 11.8% to $7.9 million in 2024, then grew by 4.86% to $8.3 million in 2025.
• Per Business Quant, the three latest RGNX Current Leases figures stand at $8.3 million (Q4 2025), $9.1 million (Q3 2025), and $8.0 million (Q2 2025).